Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 17, 2019--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18 th and 19 th.
The company will showcase ImmunoID NeXT ™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Following is a list of abstracts that will be presented at the meeting.
Scientific Poster Presentations
Title & Presenter
Day & Time
HLA allele-specific loss of heterozygosity detection
Exome scale liquid biopsy monitoring of putative
Personalis will also be exhibiting during the conference (Exhibit # 10). Representatives will be available to answer questions about the company’s cancer immunogenomics services.
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).
View source version on businesswire.com:https://www.businesswire.com/news/home/20191117005063/en/
CONTACT: Media Contact for Personalis:
650-752-1300Investor Relations Contact for Personalis:
KEYWORD: CALIFORNIA MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH GENETICS CLINICAL TRIALS
SOURCE: Personalis, Inc.
Copyright Business Wire 2019.
PUB: 11/17/2019 04:30 PM/DISC: 11/17/2019 04:30 PM